ArticleThe European respiratory journal2022
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis.
Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Alveolar Type 2 Cell Dysfunction Is Associated with Bile Acid Alterations in Experimental Hepatopulmonary Syndrome.American journal of respiratory cell and molecular biology · 2026Article
- The Importance of Liver-Lung Communication in Pulmonary Vascular Diseases.Comprehensive Physiology · 2026Review
- Successful GH Treatment of Hepatopulmonary Syndrome in Panhypopituitarism-related Advanced Liver Disease.JCEM case reports · 2026Article
- Liver transplantation for hepatopulmonary syndrome: A systematic review and meta-analysis.JHEP reports : innovation in hepatology · 2026Article
- SerpinB1a induces hepatopulmonary syndrome by promoting CTSG/AMPK/mTOR pathway-mediated mitophagy.Cell biology and toxicology · 2025Article
- Cardiopulmonary changes and its association with clinical features in noncirrhotic portal hypertension.World journal of gastroenterology · 2025Article
- Disruption of Hepatic Sinusoidal Homeostasis Leads to Hepatopulmonary Syndrome.Journal of cellular and molecular medicine · 2025Review
- Predictive models and clinical manifestations of intrapulmonary vascular dilatation and hepatopulmonary syndrome in patients with cirrhosis: Prospective comparative study.World journal of gastroenterology · 2025Article
- Hepatopulmonary syndrome in patients with porto-sinusoidal vascular disorder: Characteristics and outcome.JHEP reports : innovation in hepatology · 2025Article
- Observational
- Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome.JHEP reports : innovation in hepatology · 2025Article
- Survival of patients with hepatopulmonary syndrome related to cirrhotic and non-cirrhotic (schistosomiasis) portal hypertension.World journal of hepatology · 2025Article
- Hepatopulmonary Syndrome and Liver Transplantation: Impact on Survival and Postoperative Complications.Annals of transplantation · 2024Article
- Effects of Transjugular Intrahepatic Portosystemic Shunt on Renal and Pulmonary Function in Hepatic Decompensation with and without Hepatorenal and Hepatopulmonary Syndromes: A Review.Journal of clinical and translational hepatology · 2024Review
- Hepatopulmonary Syndrome: A Comprehensive Review.Cureus · 2024Review
- Unexplained Dyspnea: Hepatopulmonary Syndrome without Cirrhosis?Annals of the American Thoracic Society · 2023Article
- Hepatopulmonary syndrome.JHEP reports : innovation in hepatology · 2022Review
- Endothelial glycocalyx in hepatopulmonary syndrome: An indispensable player mediating vascular changes.Frontiers in immunology · 2022Review
- The Canadian Hepatopulmonary Syndrome Program: A Longitudinal Liver Transplant Experience.Journal of clinical and experimental hepatologyArticle
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
Abstract
backgroundHepatopulmonary syndrome affects 10-30% of patients with cirrhosis and portal hypertension. We evaluated the serum angiogenic profile of hepatopulmonary syndrome and assessed the clinical impact of hepatopulmonary syndrome in patients evaluated for liver transplantation.
methodsThe Pulmonary Vascular Complications of Liver Disease 2 study was a multicentre, prospective cohort study of adults undergoing their first liver transplantation evaluation. Hepatopulmonary syndrome was defined as an alveolar-arterial oxygen gradient ≥15 mmHg (≥20 mmHg if age >64 years), positive contrast-enhanced transthoracic echocardiography and absence of lung disease.
resultsWe included 85 patients with hepatopulmonary syndrome and 146 patients without hepatopulmonary syndrome. Patients with hepatopulmonary syndrome had more complications of portal hypertension and slightly higher Model for End-Stage Liver Disease-Na score compared to those without hepatopulmonary syndrome (median (interquartile range) 15 (12-19)
conclusionHepatopulmonary syndrome was associated with a profile of abnormal systemic angiogenesis, worse exercise and functional capacity, and an overall increased risk of death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.